Domvanalimab

度纳利单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameDomvanalimab
Drug Alias NameAB-154GS-0154
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAbmuno Therapeutics LLC
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterGilead Sciences IncFundacion Para El Progreso De La Oncologia En Cantabria +[5] 
Inactive CompaniesMedsir Medica Scientia Innovation ResearchWuxi Biologics Co LtdGilead Sciences Shanghai Pharmaceutical Technology Co Ltd
Active IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[17] 
Inactive IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A